|
1
|
Taga T, Tomizawa D, Takahashi H and Adachi
S: Acute myeloid leukemia in children: Current status and future
directions. Pediatr Int. 58:71–80. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rasche M, Zimmermann M, Borschel L,
Bourquin JP, Dworzak M, Klingebiel T, Lehrnbecher T, Creutzig U,
Klusmann JH and Reinhardt D: Successes and challenges in the
treatment of pediatric acute myeloid leukemia: A retrospective
analysis of the AML-BFM trials from 1987 to 2012. Leukemia.
32:2167–2177. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pikman Y and Stegmaier K: Targeted therapy
for fusion-driven high-risk acute leukemia. Blood. 132:1241–1247.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dohner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zwaan CM, Kolb EA, Reinhardt D,
Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B,
Dworzak M, Gibson BE, et al: Collaborative efforts driving progress
in pediatric acute myeloid leukemia. J Clin Oncol. 33:2949–2962.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kolb EA and Meshinchi S: Acute myeloid
leukemia in children and adolescents: Identification of new
molecular targets brings promise of new therapies. Hematology.
2015:507–513. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kayser S and Levis MJ: Advances in
targeted therapy for acute myeloid leukaemia. Br J Haematol.
180:484–500. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ding L, Ley TJ, Larson DE, Miller CA,
Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan
MD, et al: Clonal evolution in relapsed acute myeloid leukaemia
revealed by whole-genome sequencing. Nature. 481:506–510.
2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wong TN, Ramsingh G, Young AL, Miller CA,
Touma W, Welch JS, Lamprecht TL, Shen D, Hundal J, Fulton RS, et
al: Role of TP53 mutations in the origin and evolution of
therapy-related acute myeloid leukaemia. Nature. 518:552–555.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Quek L, Ferguson P, Metzner M, Ahmed I,
Kennedy A, Garnett C, Jeffries S, Walter C, Piechocki K, Timbs A,
et al: Mutational analysis of disease relapse in patients
allografted for acute myeloid leukemia. Blood Adv. 1:193–204.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Papaemmanuil E, Gerstung M, Bullinger L,
Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F,
Bolli N, et al: Genomic classification and prognosis in acute
myeloid leukemia. N Engl J Med. 374:2209–2221. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Greif PA, Hartmann L, Vosberg S, Stief SM,
Mattes R, Hellmann I, Metzeler KH, Herold T, Bamopoulos SA, Kerbs
P, et al: Evolution of cytogenetically normal acute myeloid
leukemia during therapy and relapse: An exome sequencing study of
50 patients. Clin Cancer Res. 24:1716–1726. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shiba N, Yoshida K, Shiraishi Y, Okuno Y,
Yamato G, Hara Y, Nagata Y, Chiba K, Tanaka H, Terui K, et al:
Whole-exome sequencing reveals the spectrum of gene mutations and
the clonal evolution patterns in paediatric acute myeloid
leukaemia. Br J Haematol. 175:476–489. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bolouri H, Farrar JE, Triche T Jr, Ries
RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, et al:
The molecular landscape of pediatric acute myeloid leukemia reveals
recurrent structural alterations and age-specific mutational
interactions. Nat Med. 24:103–112. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Tsukimoto I, Tawa A, Horibe K, Tabuchi K,
Kigasawa H, Tsuchida M, Yabe H, Nakayama H, Kudo K, Kobayashi R, et
al: Risk-stratified therapy and the intensive use of cytarabine
improves the outcome in childhood acute myeloid leukemia: The AML99
trial from the Japanese childhood AML cooperative study group. J
Clin Oncol. 27:4007–4013. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tomizawa D, Tawa A, Watanabe T, Saito AM,
Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, et al:
Excess treatment reduction including anthracyclines results in
higher incidence of relapse in core binding factor acute myeloid
leukemia in children. Leukemia. 27:2413–2416. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hanada T, Kanamitsu K, Chayama K, Miyamura
T, Kanazawa Y, Muraoka M, Washio K, Imada M, Kageyama M, Takeuchi
A, et al: A Long-term survivor after congenital acute myeloid
leukemia with t(8 ; 16)(p11 ; p13). Acta Med Okayama. 70:31–35.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Iwasaki Y, Nishiuchi R, Aoe M, Takahashi
T, Watanabe H, Tokorotani C, Kikkawa K and himada A: Positive
minimal residual disease of FLT3-ITD before hematopoietic stem cell
transplantation resulted in a poor prognosis of an acute myeloid
leukemia. Acta Med Okayama. 71:79–83. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Green RC, Berg JS, Grody WW, Kalia SS,
Korf BR, Martin CL, McGuire AL, Nussbaum RL, O'Daniel JM, Ormond
KE, et al: ACMG recommendations for reporting of incidental
findings in clinical exome and genome sequencing. Genet Med.
15:565–574. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: A joint consensus recommendation of the American College
of Medical Genetics and Genomics and the Association for Molecular
Pathology. Genet Med. 17:405–423. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kalia SS, Adelman K, Bale SJ, Chung WK,
Eng C, Evans JP, Herman GE, Hufnagel SB, Klein TE, Korf BR, et al:
Recommendations for reporting of secondary findings in clinical
exome and genome sequencing, 2016 update (ACMG SF v2.0): A policy
statement of the american college of medical genetics and genomics.
Genet Med. 19:249–255. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ishida H, Kanamitsu K, Washio K, Muraoka
M, Sakakibara K, Matsubara T, Kanzaki H and Shimada A: Relapsed
infant MLL-rearranged acute lymphoblastic leukemia with additional
genetic alterations. Pediatr Blood Cancer. 63:2059–2060.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Aoe M, Ishida H, Matsubara T, Karakawa S,
Kawaguchi H, Fujiwara K, Kanamitsu K, Washio K, Okada K, Shibakura
M and Shimada A: Simultaneous detection of ABL1 mutation and IKZF1
deletion in Philadelphia chromosome-positive acute lymphoblastic
leukemia using a customized target enrichment system panel. Int J
Lab Hematol. 40:427–436. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ishida H, Iguchi A, Aoe M, Takahashi T,
Tamefusa K, Kanamitsu K, Fujiwara K, Washio K, Matsubara T,
Tsukahara H, et al: Panel-based next-generation sequencing
identifies prognostic and actionable genes in childhood acute
lymphoblastic leukemia and is suitable for clinical sequencing. Ann
Hematol. 98:657–668. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sunami K, Ichikawa H, Kubo T, Kato M,
Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M,
Matsushita H, et al: Feasibility and utility of a panel testing for
114 cancer-associated genes in a clinical setting: A hospital-based
study. Cancer Sci. 110:1480–1490. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nakayama H, Tabuchi K, Tawa A, Tsukimoto
I, Tsuchida M, Morimoto A, Yabe H, Horibe K, Hanada R, Imaizumi M,
et al: Outcome of children with relapsed acute myeloid leukemia
following initial therapy under the AML99 protocol. Int J Hematol.
100:171–179. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Duployez N, Marceau-Renaut A, Boissel N,
Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C,
Figeac M, et al: Comprehensive mutational profiling of core binding
factor acute myeloid leukemia. Blood. 127:2451–2459.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Faber ZJ, Chen X, Gedman AL, Boggs K,
Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, et al: The
genomic landscape of core-binding factor acute myeloid leukemias.
Nat Genet. 48:1551–1556. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
de Rooij JDE, Branstetter C, Ma J, Li Y,
Walsh MP, Cheng J, Obulkasim A, Dang J, Easton J, Verboon LJ, et
al: Pediatric non-Down syndrome acute megakaryoblastic leukemia is
characterized by distinct genomic subsets with varying outcomes.
Nat Genet. 49:451–456. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Alexander TB, Gu Z, Iacobucci I, Dickerson
K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, et
al: The genetic basis and cell of origin of mixed phenotype acute
leukaemia. Nature. 562:373–379. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Marceau-Renaut A, Duployez N, Ducourneau
B, Labopin M, Petit A, Rousseau A, Geffroy S, Bucci M, Cuccuini W,
Fenneteau O, et al: Molecular profiling defines distinct prognostic
subgroups in childhood AML. Hemasphere. 2(e31)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Shiba N, Yoshida K, Hara Y, Yamato G,
Shiraishi Y, Matsuo H, Okuno Y, Chiba K, Tanaka H, Kaburagi T, et
al: Transcriptome analysis offers a comprehensive illustration of
the genetic background of pediatric acute myeloid leukemia. Blood
Adv. 3:3157–3169. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Meshinchi S, Alonzo TA, Stirewalt DL,
Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing
R, Lange BJ and Radich JP: Clinical implications of FLT3 mutations
in pediatric AML. Blood. 108:3654–3661. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shimada A, Taki T, Tabuchi K, Taketani T,
Hanada R, Tawa A, Tsuchida M, Horibe K, Tsukimoto I and Hayashi Y:
Tandem duplications of MLL and FLT3 are correlated with poor
prognoses in pediatric acute myeloid leukemia: A study of the
Japanese childhood AML cooperative study group. Pediatr Blood
Cancer. 50:264–269. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ivey A, Hills RK, Simpson MA, Jovanovic
JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, et al:
Assessment of minimal residual disease in Standard-risk AML. N Engl
J Med. 374:422–433. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Morita K, Kantarjian HM, Wang F, Yan Y,
Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, et
al: Clearance of somatic mutations at remission and the risk of
relapse in acute myeloid leukemia. J Clin Oncol. 36:1788–1797.
2018.PubMed/NCBI View Article : Google Scholar
|
